Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-XL

Chemistry and Biology

Volumn 11, Issue 3, 2004, Pages 389-395

  Becattini, Barbara ^a   Kitada, Shinichi ^a   Leone, Marilisa ^a   Monosov, Edward ^a   Chandler, Sharon ^a   Zhai, Dayong ^a   Kipps, Thomas J ^b   Reed, John C ^a   Pellecchia, Maurizio ^a  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; APOGOSSYPOL; BCL2L1 PROTEIN, HUMAN; DRUG DERIVATIVE; GOSSYPOL; PROTEIN BCL 2; PROTEIN BCL X;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; CONFOCAL MICROSCOPY; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SPECTROFLUOROMETRY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TIME; TUMOR CELL LINE;

ACETATES; APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DESIGN; GOSSYPOL; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICROSCOPY, CONFOCAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTO-ONCOGENE PROTEINS C-BCL-2; SPECTROMETRY, FLUORESCENCE; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 1942529509     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2004.02.020     Document Type: Article

References (41)

1. Reed J.C. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17:1999;2941-2953.
2. Reed J.C. Apoptosis-based therapies. Nat. Rev. Drug Discov. 1:2002;111-121.
3. Reed J.C. Molecular biology of chronic lymphocytic leukemia. implications for therapy Semin. Hematol. 35:1998;3-13.
4. Adams J.M., Cory S. The Bcl-2 protein family. arbiters of cell survival Science. 281:1998;1322-1326.
5. Gross A., McDonnell J.M., Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13:1999;1899-1911.
6. Amundson S.A., Myers T.G., Scudiero D., Kitada S., Reed J.C., Fornace A.J. Jr. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 60:2000;6101-6110.
7. Reed J.C., Stein C., Subasinghe C., Haldar S., Croce C.M., Yum S., Cohen J. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival. comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides Cancer Res. 50:1990;6565-6570.
8. Webb A., Cunningham D., Cotter F., Clarke P.A., di Stefano F., Ross P., Corbo M., Dziewanowska Z. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet. 349:1997;1137-1141.
9. Rudin C.M., Otterson G.A., Mauer A.M., Villalona-Calero M.A., Tomek R., Prange B., George C.M., Szeto L., Vokes E.E. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann. Oncol. 13:2002;539-545.
10. Marcucci G., Byrd J.C., Dai G., Klisovic M.I., Kourlas P.J., Young D.C., Cataland S.R., Fisher D.B., Lucas D., Chan K.K.et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood. 101:2003;425-432.
11. Reed J.C. A day in the life of the Bcl-2 protein. does the turnover rate of Bcl-2 serve as a biological clock for cellular lifespan regulation? Leuk. Res. 20:1996;109-111.
12. Adams R., Geissman T.A., Edwards J.D. Gossypol, a pigment of cottonseed. Chem. Rev. 60:1960;555-574.
13. Kitada S., Leone M., Sareth S., Zhai D., Reed J.C., Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J. Med. Chem. 46:2003;4259-4264.
14. Zhang M., Liu H., Guo R., Ling Y., Wu X., Li B., Roller P.P., Wang S., Yang D. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem. Pharmacol. 66:2003;93-103.
15. Zhu G.D., Chen D.H., Huang J.H., Chi C.S. Regioselective bromination and fluorination of apogossypol lexamethyl ether. J. Org. Chem. 57:1992;2316-2320.
16. Hajduk P.J., Olejniczak E.T., Fesik S. One-dimensional relaxation-and diffusion-edited NMR methods for screening compounds that bind to macromolecules. J. Am. Chem. Soc. 119:1997;12257-12261.
17. Zerbe O. BioNMR in Drug Research. 2003;WILEY-VCH, Weinheim, Germany.
18. Pellecchia M., Sem D.S., Wuthrich K. NMR in drug discovery. Nat. Rev. Drug Discov. 1:2002;211-219.
19. Pervushin K., Riek R., Wider G., Wuthrich K. Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. Proc. Natl. Acad. Sci. USA. 94:1997;12366-12371.
20. Dandliker W.B., Hsu M.L., Levin J., Rao B.R. Equilibrium and kinetic inhibition assays based upon fluorescence polarization. Methods Enzymol. 74(Pt C):1981;3-28.
21. Degterev A., Lugovskoy A., Cardone M., Mulley B., Wagner G., Mitchison T., Yuan J. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat. Cell Biol. 3:2001;173-182.
22. Tzung S.P., Kim K.M., Basanez G., Giedt C.D., Simon J., Zimmerberg J., Zhang K.Y., Hockenbery D.M. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat. Cell Biol. 3:2001;183-191.
23. Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene. 19:2000;6627-6631.
24. Guo B., Godzik A., Reed J.C. Bcl-G, a novel pro-apoptotic member of the Bcl-2 family. J. Biol. Chem. 276:2001;2780-2785.
25. Wang X. Cytotoxic effect of gossypol on colon carcinoma cells. Life Sci. 67:2000;2663-2671.
26. Gilbert N.E., O'Reilly J.E., Chang C.J., Lin Y.C., Brueggemeier R.W. Antiproliferative activity of gossypol and gossypolone on human breast cancer cells. Life Sci. 57:1995;61-67.
27. Wu D. An overview of the clinical pharmacology and therapeutic potential of gossypol as a male contraceptive agent and in gynaecological disease. Drugs. 38:1989;333-341.
28. Le Blanc M., Russo J., Kudelka A.P., Smith J.A. An in vitro study of inhibitory activity of gossypol, a cottonseed extract, in human carcinoma cell lines. Pharmacol. Res. 46:2002;551-555.
29. Qui J., Levin L.R., Buck J., Ridenberg M.M. Different pathways of cell killing by gossypol anantiomers. Exp. Biol. Med. 227:2002;398-401.
30. Stein R.C., Joseph A.E., Matlin S.A., Cunningham D.C., Ford H.T., Coombes R.C. A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother. Pharmacol. 30:1992;480-482.
31. Flack M.R., Pyle R.G., Mullen N.M., Lorenzo B., Wu Y.W., Knazek R.A., Nisula B.C., Reidenberg M.M. Oral gossypol in the treatment of metastatic adrenal cancer. J. Clin. Endocrinol. Metab. 76:1993;1019-1024.
32. Wang X. Cytotoxic effect of gossypol in the treatment of metastic adrenal cancer. J. Clin. Endrocrinol. Metab. 76:1993;1019-1024.
33. Van Poznak C., Seidman A.D., Reidenberg M.M., Moasser M.M., Sklarin N., Van Zee K., Borgen P., Gollub M., Bacotti D., Yao T.J.et al. Oral gossypol in the treatment of patients with refractory metastatic breast cancer. a phase I/ II clinical trial Breast Cancer Res. Treat. 66:2001;239-248.
34. Shelley M.D., Hartley L., Groundwater P.W., Fish R.G. Structure-activity studies on gossypol in tumor cell lines. Anticancer Drugs. 11:2000;209-216.
35. Dao V.T., Gaspard C., Mayer M., Werner G.H., Nguyen S.N., Michelot R.J. Synthesis and cytotoxicity of gossypol related compounds. Eur. J. Med. Chem. 35:2000;805-813.
36. Liang X.S., Rogers A.J., Webber C.L., Ormsby T.J., Tiritan M.E., Matlin S.A., Benz C.C. Developing gossypol derivatives with enhanced antitumor activity. Invest. New Drugs. 13:1995;181-186.
37. Kramer B., Rarey M., Lengauer T. Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking. Proteins. 37:1999;228-241.
38. Teschner M., Henn C., Vollhardt H., Reiling S., Brickmann J. Texture mapping. a new tool for molecular graphics J. Mol. Graph. 12:1994;98-105.
39. Seshadri T.R., Sharma N.N. An efficient method for the preparation of (+)-apogossypol. Indian J. Chem. 15B:1977;1069-1070.
40. Sattler M., Liang H., Nettesheim D., Meadows R.P., Harlan J.E., Eberstadt M., Yoon H.S., Shuker S.B., Chang B.S., Minn A.J.et al. Structure of Bcl-xL-Bak peptide complex. recognition between regulators of apoptosis Science. 275:1997;983-986.
41. Chenson B.D. National Cancer Institute-sponsored working group guidelines for chronic lympocytic leukemia. revised guidelines for diagnosis and treatment Blood. 87:1996;4990-4997.